BioSpace News Archive

BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.

MedAvail Holdings, Inc. today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets.

Orchard Therapeutics today presented new data from the company’s hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).

Veeva Systems (NYSE: VEEV) today announced Veeva Link MedTech , a data application developed for medtech companies to identify scientific experts, personalize engagement, and map activities across the healthcare ecosystem.

Boston Pharmaceuticals today announced that new results from its ongoing Phase 2a study evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH) were accepted as a late-breaking poster presentation at the European Association for the Study of the Liver International Liver Congress, June 21-24 in Vienna, Austria.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting.

Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “A Phase 1b Randomized Clinical Trial of CT1812 to Measure Aβ Oligomer Displacement in Alzheimer’s Disease Using an Indwelling CSF Catheter” (doi: 10.1186/s40035-023-00358-w) has been published in the journal, Translational Neurodegeneration.

Ameresco, Inc. today announced that members of its management team will attend the following investor conferences.

Impulse Dynamics plc announced the completion of the first implantation for the INTEGRA-D clinical trial, designed to evaluate the safety and efficacy of two proven cardiac therapies combined — CCM ® and an implantable cardioverter defibrillator (ICD) — in a single device (CCM-D).